PTC Therapeutics (BH3) Stock Overview
A biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
BH3 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
PTC Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$54.16 |
| 52 Week High | US$75.00 |
| 52 Week Low | US$32.00 |
| Beta | 0.55 |
| 1 Month Change | -4.14% |
| 3 Month Change | -13.34% |
| 1 Year Change | 26.54% |
| 3 Year Change | 9.19% |
| 5 Year Change | 61.19% |
| Change since IPO | 305.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| BH3 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -8.6% | 3.3% | -0.4% |
| 1Y | 26.5% | -4.2% | 3.0% |
Return vs Industry: BH3 exceeded the German Biotechs industry which returned -4.7% over the past year.
Return vs Market: BH3 exceeded the German Market which returned 1.7% over the past year.
Price Volatility
| BH3 volatility | |
|---|---|
| BH3 Average Weekly Movement | 6.3% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in DE Market | 12.4% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: BH3 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: BH3's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 991 | Matt Klein | www.ptcbio.com |
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington’s disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich’s ataxia.
PTC Therapeutics, Inc. Fundamentals Summary
| BH3 fundamental statistics | |
|---|---|
| Market cap | €4.56b |
| Earnings (TTM) | €581.54m |
| Revenue (TTM) | €1.47b |
Is BH3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BH3 income statement (TTM) | |
|---|---|
| Revenue | US$1.73b |
| Cost of Revenue | US$502.26m |
| Gross Profit | US$1.23b |
| Other Expenses | US$545.75m |
| Earnings | US$682.64m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 07, 2026
| Earnings per share (EPS) | 8.23 |
| Gross Margin | 70.98% |
| Net Profit Margin | 39.44% |
| Debt/Equity Ratio | -1,263.9% |
How did BH3 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/30 18:24 |
| End of Day Share Price | 2026/04/30 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PTC Therapeutics, Inc. is covered by 35 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Luke Herrmann | Baird |
| Joel Beatty | Baird |
| null null | Baird |